12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Deals

Hubei Qianjiang, TNI BioTech deal

TNI and Hubei partnered to co-develop TNI's cancer therapeutic candidates IRT-101 and IRT-102 in China. Hubei will fund all clinical development and has committed an additional RMB10 million ($1.6 million) to fund preclinical trials. In exchange, Hubei will have rights to commercialize the products...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >